Purpose: To study the effects of adding intravitreal bevacizumab (Avastin) to conventional LASER treatment on regression of retinal neovascularization in threshold ROP.

Methods: Intravitreal injection of bevacizumab (1.25 mg) in one eye of each of three newborns with threshold ROP was performed in addition to laser treatment. The other eye of each patient was treated with laser alone. Changes in retinal neovascularization, its regression and unfavorable anatomical outcome were assessed on fundus photographs by Retcam and frequent funduscopy. ERG was performed four months after injection.

Results: ROP regressed in both eyes at the same time. There were no differences in normal retinal vascularization. We had no adverse effects due to injection including cataract, endophthalmitis or vitreous hemorrhage. We didn’t observe any differences in ERG between two eyes.

Conclusion: Intravitreal injection of bevacizumab seems to have no adverse effect in newborns with threshold ROP. There were no differences in regression of neovascularization between two eyes. It is recommended to perform more studies in order to assess its effect.